Get access

Novel therapies for oral lichen planus

Authors

  • Kobkan Thongprasom,

    1. Oral Medicine Department, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand
    Search for more papers by this author
  • Chanwit Prapinjumrune,

    1. Oral Medicine Department, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand
    Search for more papers by this author
  • Marco Carrozzo

    Corresponding author
    1. Oral Medicine Department, Center for Oral Health Research, Newcastle University, Newcastle upon Tyne, UK
    • Correspondence: Prof. Marco Carrozzo, MD, DSM, Professor of Oral Medicine, School of Dental Sciences, University of Newcastle upon Tyne, Framlington Place, Newcastle upon Tyne NE2 4BW, UK. Tel: 0044 191 222 7818, Fax: 0044 191 222 6137, E-mail:marco.carrozzo@ncl.ac.uk

    Search for more papers by this author

Abstract

Oral lichen planus (OLP) is a chronic mucocutaneous disorder commonly found in middle-aged women. Despite the progress in research and advance in knowledge on OLP, a successful management is still difficult to achieve. The main aim of OLP treatment is to control the symptoms of the affected patients. Steroids and other immunosuppressive drugs have been recommended and widely used in the treatment of OLP. Topical corticosteroids are the mainstay of OLP treatment, but strong evidence on their effectiveness is lacking. The effectiveness of alternative ways of managing OLP has been recently reported. Topical aloe vera, topical pimecrolimus and oral curcuminoids are the most promising of the new treatment modalities. Other interesting modalities are topically applied thalidomide and amlexanox. Nevertheless, the careful assessment between the risks and benefits of these drugs is crucial and larger and well-conducted trials need to confirm the above encouraging results.

Ancillary